203 related articles for article (PubMed ID: 21871426)
1. p52 Activation in monomorphic B-cell posttransplant lymphoproliferative disorder/diffuse large B-cell lymphoma without BAFF-R expression.
Proust A; Rincé P; Creidy R; Lazure T; Joab I; Garçon L; Fabre M; Guettier C; Raphael M
Am J Pathol; 2011 Oct; 179(4):1630-7. PubMed ID: 21871426
[TBL] [Abstract][Full Text] [Related]
2. CD30 expression and survival in posttransplant lymphoproliferative disorders.
Kinch A; Amini RM; Hollander P; Molin D; Sundström C; Enblad G
Acta Oncol; 2020 Jun; 59(6):673-680. PubMed ID: 32102582
[No Abstract] [Full Text] [Related]
3. Epstein-Barr virus latency patterns in polymorphic lymphoproliferative disorders and lymphomas in immunodeficiency settings: Diagnostic implications.
Volaric AK; Saleem A; Younes SF; Zhao S; Natkunam Y
Ann Diagn Pathol; 2024 Jun; 70():152286. PubMed ID: 38447253
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
Ok CY; Xu-Monette ZY; Li L; Manyam GC; Montes-Moreno S; Tzankov A; Visco C; Dybkær K; Routbort MJ; Zhang L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Rao H; Møller MB; Winter JN; Piris MA; Wang SA; Medeiros LJ; Young KH
Mod Pathol; 2015 Sep; 28(9):1202-13. PubMed ID: 26111978
[TBL] [Abstract][Full Text] [Related]
5. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T
PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597
[TBL] [Abstract][Full Text] [Related]
6. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G
Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103
[TBL] [Abstract][Full Text] [Related]
7. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
8. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
Johnson LR; Nalesnik MA; Swerdlow SH
Am J Surg Pathol; 2006 Dec; 30(12):1604-12. PubMed ID: 17122518
[TBL] [Abstract][Full Text] [Related]
9. Frequent downregulation of BTB and CNC homology 2 expression in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Noujima-Harada M; Takata K; Miyata-Takata T; Sakurai H; Igarashi K; Ito E; Nagakita K; Taniguchi K; Ohnishi N; Omote S; Tabata T; Sato Y; Yoshino T
Cancer Sci; 2017 May; 108(5):1071-1079. PubMed ID: 28256087
[TBL] [Abstract][Full Text] [Related]
10. Mutational landscape of B-cell post-transplant lymphoproliferative disorders.
Menter T; Juskevicius D; Alikian M; Steiger J; Dirnhofer S; Tzankov A; Naresh KN
Br J Haematol; 2017 Jul; 178(1):48-56. PubMed ID: 28419429
[TBL] [Abstract][Full Text] [Related]
11. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.
Pham LV; Fu L; Tamayo AT; Bueso-Ramos C; Drakos E; Vega F; Medeiros LJ; Ford RJ
Blood; 2011 Jan; 117(1):200-10. PubMed ID: 20889926
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling.
Menter T; Dickenmann M; Juskevicius D; Steiger J; Dirnhofer S; Tzankov A
Hematol Oncol; 2017 Jun; 35(2):187-197. PubMed ID: 26799990
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders.
Morscio J; Dierickx D; Ferreiro JF; Herreman A; Van Loo P; Bittoun E; Verhoef G; Matthys P; Cools J; Wlodarska I; De Wolf-Peeters C; Sagaert X; Tousseyn T
Am J Transplant; 2013 May; 13(5):1305-16. PubMed ID: 23489474
[TBL] [Abstract][Full Text] [Related]
14. Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival.
Huang YC; Lin SJ; Lin KM; Chou YC; Lin CW; Yu SC; Chen CL; Shen TL; Chen CK; Lu J; Chen MR; Tsai CH
Blood; 2016 Sep; 128(12):1578-89. PubMed ID: 27338098
[TBL] [Abstract][Full Text] [Related]
15. Decoding the molecular heterogeneity of pediatric monomorphic post-solid organ transplant lymphoproliferative disorders.
Salmerón-Villalobos J; Castrejón-de-Anta N; Guerra-García P; Ramis-Zaldivar JE; López-Guerra M; Mato S; Colomer D; Diaz-Crespo F; Menarguez J; Garrido-Pontnou M; Andrés M; García-Fernández E; Llavador M; Frigola G; García N; González-Farré B; Martín-Guerrero I; Garrido-Colino C; Astigarraga I; Fernández A; Verdú-Amorós J; González-Muñíz S; González B; Celis V; Campo E; Balagué O; Salaverria I
Blood; 2023 Aug; 142(5):434-445. PubMed ID: 37053555
[TBL] [Abstract][Full Text] [Related]
16. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?
Leblond V; Davi F; Charlotte F; Dorent R; Bitker MO; Sutton L; Gandjbakhch I; Binet JL; Raphael M
J Clin Oncol; 1998 Jun; 16(6):2052-9. PubMed ID: 9626203
[TBL] [Abstract][Full Text] [Related]
17. The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21).
Kuo SH; Tsai HJ; Lin CW; Yeh KH; Lee HW; Wei MF; Shun CT; Wu MS; Hsu PN; Chen LT; Cheng AL
J Pathol; 2017 Feb; 241(3):420-433. PubMed ID: 27873317
[TBL] [Abstract][Full Text] [Related]
18. Increased MYC expression without MYC gene translocation in patients with the diffuse large B-cell-lymphoma subtype of iatrogenic immunodeficiency-associated lymphoproliferative disorders.
Kabasawa N; Shiozawa E; Murai S; Homma M; Uesugi Y; Matsui T; Nakata A; Shimada S; Sasaki Y; Baba Y; Watanuki M; Arai N; Fujiwara S; Kawaguchi Y; Tsukamoto H; Uto Y; Yanagisawa K; Hattori N; Sakai H; Harada H; Nakamaki T; Takimoto M; Yamochi-Onizuka T
J Clin Exp Hematop; 2021; 61(3):120-125. PubMed ID: 34511544
[TBL] [Abstract][Full Text] [Related]
19. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
20. A role of both NF-κB pathways in expression and transcription regulation of BAFF-R gene in multiple myeloma cells.
Shen X; Zhu W; Zhang X; Xu G; Ju S
Mol Cell Biochem; 2011 Nov; 357(1-2):21-30. PubMed ID: 21607696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
